MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
References related to functions published in Clin. Cancer Res.
| PMID | Journal | Published Date | Author | Title |
|---|---|---|---|---|
| 15240523 | Clin. Cancer Res. | 2004 | Helft PR et al. | A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. |
| 20805300 | Clin. Cancer Res. | 2010 | Junutula JR et al. | Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. |
| 19509168 | Clin. Cancer Res. | 2009 | Al-Katib AM et al. | Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. |
| 22003072 | Clin. Cancer Res. | 2011 | Blanc V et al. | SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. |
| 23426279 | Clin. Cancer Res. | 2013 | Carol H et al. | The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. |
| 24879797 | Clin. Cancer Res. | 2014 | Amiri-Kordestani L et al. | FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. |